15:24 EDT Novavax (NVAX) down 10% after WSJ report on FDA request for additional vaccine trial
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax has improved clarity on path forward for Nuvaxovid, says BofA
- Unusually active option classes on open April 23rd
- Novavax’s Biologics License Application Nears Approval
- Novavax says received formal PMC request from FDA related to COVID vaccine
- Promising Results from Novavax’s SHIELD-Utah Study Boost Buy Rating Amid Vaccine Market Dynamics